Myelodysplastic Syndromes
Association Between Transfusion Status and Overall Survival in Patients With Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis
... MDS, myelodysplastic syndromes; NA, not available; NR, not reported; O, overlapping cohort; RAEB-T, refractory anemia with excess blasts in transition; RCT, randomized controlled trial; RS, ringed ...
49
IL32 expression in peripheral blood CD3+ cells from myelodysplastic syndromes patients
... Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by ineffective hematopoiesis and risk of leukemia ...
6
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
... Abstract: Myelodysplastic syndromes (MDS) are a varied group of diseases leading to significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, ...
9
Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast
... Myelodysplastic syndromes are characterized by ineffect- ive hematopoiesis with blood cytopenias and morpho- logical dysplasia [1–5]. MDS is generally considered a preleukemic disorder and is prevalent in ...
7
Safety and efficacy of azacitidine in myelodysplastic syndromes
... Hypomethylating agents are a group of chemotherapeutic drugs with the capacity to induce transient DNA hypomethylation, an important mechanism in the treatment of myelodysplastic syndromes (MDS). Two ...
9
Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
... Myelodysplastic syndromes (MDS) are clonal hemato- poietic stem cell (HSC) disorders characterized by refrac- tory cytopenias with dysplasia as a result of ineffective hematopoiesis ...
9
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
... significance of detecting pseudo-Pelger-Huet anomalies and micro-meg- akaryocytes in myelodysplastic syndrome. Br J Haematol. 1986;63:665–9. 10. Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, ...
8
Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes
... Aberrant T cell phenotype is one of the characteristics of myelodysplastic syndromes (MDS). In this study, we detected an increased concentration of IL-15 in the plasma of MDS patients ( n = 20) compared ...
10
Recent Advances in Stem Cell Therapy for Myelodysplastic Syndromes
... like myelodysplastic syndromes, clonal hematopoietic disorders where blood-forming cells are damaged in the bone ...cure myelodysplastic syndromes, with a reduced risk of rejection and ...
6
Original Article Differential expression of ACINUS variants in bone marrow in myelodysplastic syndromes
... Abstract: Hematopoietic cells in the bone marrow of myelodysplastic syndromes (MDS) exhibit a complex pattern of cellular dynamics, showing active cellproliferation, as well as frequent apoptosis. To ...
9
Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
... Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies. Although most MDS patients have normal or increased BM cellularity (NH-MDS), some have hypocellular BM (h-MDS). The ...
12
DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population
... Results: Gene-based analysis showed nine candidate single nucleotide polymorphisms significantly associated with the disease susceptibility (q-value < 0.05). Four of these polymorphisms were located in oxidative ...
6
Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes
... In this paper we presented the first systematic profiling for small RNAs in Myelodysplastic Syndromes using next gen- eration sequencing on the current Illumina Genome Ana- lyzer IIx platform. A custom data ...
16
Clinical significance of hyaluronan levels and its pro osteogenic effect on mesenchymal stromal cells in myelodysplastic syndromes
... MDS: myelodysplastic syndromes; AML: acute myeloid leukemia; BM: bone marrow; OS: overall survival; MSC: mesenchymal stromal cells; MNC: mononuclear cells; SLD: single lineage dys‑ plasia; RS: ring ...
9
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
... Abstract: Myelodysplastic syndromes (MDS) are clonal bone marrow malignancies characterized by peripheral cytopenias and dysplastic changes in the bone marrow with various clinical ...
13
Signal transduction inhibitors in treatment of myelodysplastic syndromes
... Myelodysplastic syndromes (MDS) encompass a spectrum of hematologic diseases characterized by ineffective hema- topoiesis in the marrow that leads to refractory ...
11
The Molecular Anatomy of Myelodysplastic Syndromes: An Update
... Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haemopoietic disorders arising from a haematopoietic stem cell. They are characterised by inefficient haematopoiesis, manifesting with ...
23
Cytogenetic Abnormalities in Myelodysplastic Syndromes: An Overview
... Karyotype is one of the main constituents of the International Prognostic Scoring System (IPSS) and revised- IPSS that are the cornerstones for the prognostication of patients with myelodysplastic syndromes ...
9
SIVA, a target of p53, is downregulated in myelodysplastic syndromes
... and myelodysplastic syndromes (MDS), strong p53 protein ex- pression has been associated with TP53 mutations [4 – 7] and TP53 mutations have been associated with poor prog- nosis [8 – ...
7
The role of azacitidine in the management of myelodysplastic syndromes (MDS)
... Abstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for transfor- mation to acute ...
12